Daewoong Pharma's AI ECG Solution, A New Era In Health Checkups

Seers, a digital healthcare company, has introduced mobiCARE, a highly portable device weighing only 19 grams. It's user-friendly, effortlessly attaching and detaching without disrupting everyday activities like showering or exercising. In contrast to conventional ECG tests that capture heart activity for a mere 10 seconds during a checkup, mobiCARE offers continuous ECG monitoring for up to nine days, significantly enhancing the detection of elusive heart conditions. This partnership will enable the integration of AI-powered ECG testing solutions at 17 KAHP health screening centers. The AI ECG test merges wearable technology with artificial intelligence to identify heart diseases, including arrhythmias.

This innovative approach helps uncover previously undetected heart issues in patients during health screenings. With this agreement, mobiCARE extends its services from outpatient markets to the health screening sector. Before its official launch, Daewoong Pharmaceutical and KAHP validated the efficacy of AI ECG tests using mobiCARE. In preliminary trials involving 71 participants, arrhythmias were detected in approximately 15% of the cases, demonstrating the device's effectiveness in early heart disease diagnosis. KAHP will offer two options for AI ECG testing -- same-day testing and a 24-hour test, catering to patient preferences. The 24-hour test includes a convenient home collection service, reducing the hassle of returning the device after wearing it home from the screening center.

KAHP President Kim In-One said, "As the elderly population increases and dietary habits become more westernized, the number of arrhythmia patients is also rising. By combining 12-lead ECG and continuous ECG, we aim to increase the detection rate of not only heart diseases but also arrhythmia, thereby improving treatment efficiency through early detection."

Daewoong CO Lee Chang-jae further added, "MobiCare is garnering attention as a next-generation ECG testing solution that enhances accuracy, convenience, and cost-effectiveness by addressing the shortcomings of existing devices like Holter monitors. Through this supply contract, the company aims to popularize AI ECG testing solutions, enhance early diagnosis, and improve the treatment efficiency of related diseases, ultimately contributing to public health.”